Vaxcyte reports positive Phase 3 data for VAX‑31, meeting all primary endpoints

Vaxcyte announced on Oct 5 2026 that its 31‑valent pneumococcal conjugate vaccine VAX‑31 cleared the pivotal OPUS‑1 Phase 3 trial, achieving all prespecified primary immunogenicity and safety endpoints. The vaccine demonstrated non‑inferiority (lower‑bound 95 % CI > 0.667) versus Prevnar 20 and Capvaxive 21 across all shared serotypes and superiority for three unique serotypes. The company said the results form the cornerstone of a Biologics License Application expected in the first half of 2028, with additional trial data slated for the first half of 2027.

Guggenheim raised its price target to $125, citing the strong Phase 3 results and a 95 % probability of regulatory approval (source 10). The positive data positions Vaxcyte to compete in the $3‑$6 billion adult pneumococcal vaccine market and could drive further share price appreciation.

  • 1The OPUS‑1 trial results were released on Oct 5 2026.
  • 2VAX‑31 met all prespecified co‑primary immunogenicity endpoints in adults 50 years and older, with non‑inferiority criteria met at >0.667 for all 28 shared serotypes.
  • 3Three serotypes unique to VAX‑31 met the superiority criterion (LBCI > 2.0).
  • 4The vaccine’s safety profile was comparable to PCV20 and PCV21 across all age groups.
  • 5Vaxcyte plans to file a Biologics License Application in the first half of 2028.
  • 6Topline results from OPUS‑2 and OPUS‑3 are expected in the first half of 2027.
  • Participant count in the OPUS‑1 trial: 4,047 reported by one source (6) versus “3,500+” reported by another (16).

Sources